Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment

Objective: Residual ovarian syndrome (ROS) occurs after a hysterectomy in which one or both ovaries have been preserved and cause chronic pelvic pain, an asymptomatic pelvic mass, or dyspareunia. We present a case with classic symptoms and imaging and pathology findings, and review the treatment of...

Full description

Bibliographic Details
Main Authors: Shao-Chi Fu, Her-Young Su
Format: Article
Language:English
Published: Elsevier 2018-10-01
Series:Taiwanese Journal of Obstetrics & Gynecology
Online Access:http://www.sciencedirect.com/science/article/pii/S1028455918301943
id doaj-959a2afcd85d47199e35080548309732
record_format Article
spelling doaj-959a2afcd85d47199e350805483097322020-11-24T21:48:26ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592018-10-01575753754Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatmentShao-Chi Fu0Her-Young Su1Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, TaiwanCorresponding author. 5F, 325, Section 2, Cheng-Gong Road, Nei-Hu District, 114, Taipei, Taiwan.; Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, TaiwanObjective: Residual ovarian syndrome (ROS) occurs after a hysterectomy in which one or both ovaries have been preserved and cause chronic pelvic pain, an asymptomatic pelvic mass, or dyspareunia. We present a case with classic symptoms and imaging and pathology findings, and review the treatment of residual ovarian syndrome. Case report: A 35-year-old woman with a diagnosis of ROS. Conclusion: Based on previous literature, almost 50% of patients with ROS require surgery for their symptoms. Treatment of ROS with gonadotropin-releasing hormone analogs or high dose progestogens may be helpful. However, there are limited data supporting the efficacy of pharmacologic therapy. Patients receiving pharmacologic therapy should be counseled about the limited data supporting the efficacy of this approach, the lack of a histologic diagnosis, and the risk of ovarian cancer in residual tissue. Keywords: Residual ovarian syndrome, Pelvic pain, Gonadotropin-releasing hormone analogshttp://www.sciencedirect.com/science/article/pii/S1028455918301943
collection DOAJ
language English
format Article
sources DOAJ
author Shao-Chi Fu
Her-Young Su
spellingShingle Shao-Chi Fu
Her-Young Su
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment
Taiwanese Journal of Obstetrics & Gynecology
author_facet Shao-Chi Fu
Her-Young Su
author_sort Shao-Chi Fu
title Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment
title_short Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment
title_full Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment
title_fullStr Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment
title_full_unstemmed Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment
title_sort residual ovarian syndrome: a case report with classic symptoms, imaging and pathology findings, and treatment
publisher Elsevier
series Taiwanese Journal of Obstetrics & Gynecology
issn 1028-4559
publishDate 2018-10-01
description Objective: Residual ovarian syndrome (ROS) occurs after a hysterectomy in which one or both ovaries have been preserved and cause chronic pelvic pain, an asymptomatic pelvic mass, or dyspareunia. We present a case with classic symptoms and imaging and pathology findings, and review the treatment of residual ovarian syndrome. Case report: A 35-year-old woman with a diagnosis of ROS. Conclusion: Based on previous literature, almost 50% of patients with ROS require surgery for their symptoms. Treatment of ROS with gonadotropin-releasing hormone analogs or high dose progestogens may be helpful. However, there are limited data supporting the efficacy of pharmacologic therapy. Patients receiving pharmacologic therapy should be counseled about the limited data supporting the efficacy of this approach, the lack of a histologic diagnosis, and the risk of ovarian cancer in residual tissue. Keywords: Residual ovarian syndrome, Pelvic pain, Gonadotropin-releasing hormone analogs
url http://www.sciencedirect.com/science/article/pii/S1028455918301943
work_keys_str_mv AT shaochifu residualovariansyndromeacasereportwithclassicsymptomsimagingandpathologyfindingsandtreatment
AT heryoungsu residualovariansyndromeacasereportwithclassicsymptomsimagingandpathologyfindingsandtreatment
_version_ 1725892187295580160